tiprankstipranks
Strata Skin Sciences Inc (SSKN)
OTHER OTC:SSKN
US Market

Strata Skin Sciences (SSKN) Price & Analysis

Compare
244 Followers

SSKN Stock Chart & Stats

$1.30
$0.03(0.99%)
At close: 4:00 PM EST
$1.30
$0.03(0.99%)

Bulls Say, Bears Say

Bulls Say
Leadership And StrategyDr. Dolev Rafaeli was reappointed as CEO and has implemented a strategic turnaround plan focused on direct-to-consumer marketing to drive patient volume.
Market Growth PotentialSignificant opportunities in the dermatology market, with the potential for growth in the global treatment market expected to reach $44B by 2031.
Product AdvantagesThe FDA-cleared XTRAC therapy offers several advantages in the treatment of psoriasis, backed by peer-reviewed study data.
Bears Say
International RevenueThe 2Q25 revenue miss was primarily due to international weakness related to tariffs which could continue to pressure the topline through the remainder of 2025.

Strata Skin Sciences News

SSKN FAQ

What was Strata Skin Sciences Inc’s price range in the past 12 months?
Strata Skin Sciences Inc lowest stock price was $0.12 and its highest was $3.86 in the past 12 months.
    What is Strata Skin Sciences Inc’s market cap?
    Strata Skin Sciences Inc’s market cap is $1.44M.
      When is Strata Skin Sciences Inc’s upcoming earnings report date?
      Strata Skin Sciences Inc’s upcoming earnings report date is May 20, 2026 which is in 54 days.
        How were Strata Skin Sciences Inc’s earnings last quarter?
        Currently, no data Available
        Is Strata Skin Sciences Inc overvalued?
        According to Wall Street analysts Strata Skin Sciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Strata Skin Sciences Inc pay dividends?
          Strata Skin Sciences Inc does not currently pay dividends.
          What is Strata Skin Sciences Inc’s EPS estimate?
          Strata Skin Sciences Inc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Strata Skin Sciences Inc have?
          Strata Skin Sciences Inc has 5,888,199 shares outstanding.
            What happened to Strata Skin Sciences Inc’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Strata Skin Sciences Inc?
            Currently, no hedge funds are holding shares in SSKN
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              Company Description

              Strata Skin Sciences Inc

              STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.

              Strata Skin Sciences (SSKN) Earnings & Revenues

              SSKN Earnings Call

              Q3 2025
              0:00 / 0:00
              Earnings Call Sentiment|Neutral
              The earnings call presented a mixed sentiment. While there were significant advancements in the expansion of addressable markets and successful litigation outcomes, the overall financial performance was hampered by a decline in total and equipment revenue due to international trade challenges.View all SSKN earnings summaries
              Similar Stocks
              Company
              Price & Change
              Follow
              Fonar
              Sintx Technologies
              Cytosorbents
              Xtant Medical Holdings

              Ownership Overview

              2.92%0.74%16.49%79.58%
              16.49% Other Institutional Investors
              79.58% Public Companies and
              Individual Investors

              Options Prices

              Currently, No data available
              ---
              Popular Stocks